Plant Name: Brachyglottis bidwillii
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NMUR2; | |
| FFAR1; FFAR4; ADRA2C; ADRA2A; | |
| ACHE; GAA; | |
| RECQL; TDP1; TERT; PKM; GLO1; ALOX12; AKR1B1; HSD17B10; NOX4; HPGD; ALOX15; ALDH1A1; HSD17B1; USP2; TNKS; PARP1; TNKS2; CD38; POLB; | |
| CFTR; | |
| GSK3B; SYK; FLT3; MAPK1; CDK6; CSNK2A1; | |
| CA2; CA12; CA7; CA4; | |
| PPARA; PPARD; PPARG; | |
| AR; | |
| ESR1; ESR2; | |
| NR1I2; | |
| ALOX5; MAOA; PTGS1; PTGS2; XDH; | |
| KDM4E; | |
| MMP9; MMP12; MMP2; | |
| HIF1A; TP53; | |
| ABCG2; ABCC1; | |
| NPC1; LMNA; APP; TTR; MAPT; FABP3; THPO; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 6.947E-10 | 2.224E-07 | AR, CA12, CA2, CA4, CA7, ESR1, ESR2, GLO1, MMP12, MMP2, MMP9, NR1I2, PARP1, PPARA, PPARD, PPARG, TNKS, TP53 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.984E-09 | 5.683E-07 | ADRA2A, CA2, CA7, CD38, CDK6, CFTR, HIF1A, MAPK1, NPC1, PARP1, PTGS2, SYK, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 2.643E-09 | 7.114E-07 | ALOX12, ALOX15, ALOX5, HPGD, PTGS2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.980E-09 | 1.910E-06 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, XDH |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.121E-08 | 2.543E-06 | CA2, CA7, CFTR, HIF1A, MAPK1, NPC1, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.575E-08 | 3.361E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.995E-08 | 4.138E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.502E-08 | 5.091E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4, PTGS1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 9.845E-08 | 1.675E-05 | ABCC1, ALOX12, ALOX15, ALOX5, SYK |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.348E-07 | 3.626E-05 | CA12, CA2, CA4, CA7 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 5.445E-07 | 7.504E-05 | AR, ESR1, ESR2, NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.061E-07 | 8.197E-05 | CA12, CA2, CA4, CA7, CFTR |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 8.060E-07 | 1.045E-04 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.012E-06 | 1.259E-04 | CYP1A1, POLB, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 1.071E-06 | 1.310E-04 | AR, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.234E-06 | 1.484E-04 | HPGD, MMP2, MMP9, TERT |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 2.200E-06 | 2.508E-04 | AR, ESR1, ESR2, NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 2.468E-06 | 2.770E-04 | HIF1A, LMNA, PPARD, PTGS2, TERT, TP53 |
| BP | GO:0065007; biological regulation | GO:0043085; positive regulation of catalytic activity | 3.358E-06 | 3.620E-04 | ADRA2A, ADRA2C, ALDH1A1, APP, ESR1, FLT3, GSK3B, HIF1A, MAPK1, MAPT, NMUR2, NOX4, PPARG, SYK, TERT, TNKS, TSHR, XDH |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 3.987E-06 | 4.173E-04 | AR, ESR1, ESR2, NR1I2, PPARA, PPARD, PPARG |
| BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 4.613E-06 | 4.650E-04 | APP, CDK6, GSK3B, HIF1A, MAPK1, MAPT, PARP1, PTGS2, SYK, TERT, TP53, XDH |
| BP | GO:0007610; behavior | GO:0007610; behavior | 4.757E-06 | 4.745E-04 | APP, GAA, HIF1A, MAPK1, MAPT, NMUR2, NPC1, PPARA, PTGS2, TP53, USP2 |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 5.368E-06 | 5.172E-04 | ADRA2A, ALOX12, APP, HIF1A, MAPK1, MMP9, NOX4, PTGS2, TERT, TP53 |
| BP | GO:0023052; signaling | GO:0032024; positive regulation of insulin secretion | 5.428E-06 | 5.206E-04 | CD38, CFTR, FFAR1, HIF1A, PPARD |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 5.848E-06 | 5.489E-04 | CA2, CA7, CFTR |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.848E-06 | 5.489E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 5.848E-06 | 5.489E-04 | ABCC1, ABCG2, NR1I2 |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 8.020E-06 | 7.013E-04 | AR, CYP19A1, ESR1 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 9.550E-06 | 8.187E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.066E-05 | 9.012E-04 | CYP1A2, CYP3A4, NR1I2 |
| BP | GO:0022414; reproductive process | GO:0007566; embryo implantation | 1.190E-05 | 9.888E-04 | MMP2, MMP9, PPARD, PTGS2 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.370E-05 | 1.081E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 1.370E-05 | 1.081E-03 | PTGS1, PTGS2 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.370E-05 | 1.081E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.370E-05 | 1.081E-03 | ALOX12, ALOX15 |
| BP | GO:0050896; response to stimulus | GO:0048545; response to steroid hormone | 1.725E-05 | 1.327E-03 | AR, CA2, CD38, FLT3, NPC1, PARP1, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0014074; response to purine-containing compound | 1.743E-05 | 1.337E-03 | APP, CFTR, NOX4, PPARG, PTGS2, TP53 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 2.147E-05 | 1.607E-03 | MAPT, NOX4, PTGS2, TP53, XDH |
| BP | GO:0051179; localization | GO:0070198; protein localization to chromosome, telomeric region | 2.188E-05 | 1.632E-03 | TERT, TNKS, TNKS2 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 3.252E-05 | 2.322E-03 | MAPK1, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 3.252E-05 | 2.322E-03 | CYP1A1, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0019902; phosphatase binding | 3.361E-05 | 2.376E-03 | MAPK1, MAPT, PPARA, PPARG, SYK, TP53 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.101E-05 | 2.764E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 4.101E-05 | 2.764E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 4.101E-05 | 2.764E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 4.101E-05 | 2.764E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 4.101E-05 | 2.764E-03 | ADRA2A, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 4.101E-05 | 2.764E-03 | ALOX12, ALOX15 |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 4.874E-05 | 3.236E-03 | NOX4, PARP1, POLB, TP53 |
| MF | GO:0005488; binding | GO:0043621; protein self-association | 4.874E-05 | 3.236E-03 | ACHE, FLT3, PPARG, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 4.945E-05 | 3.273E-03 | ADRA2C, ALOX12, APP, CD38, CDK6, FFAR4, GSK3B, HIF1A, LMNA, PPARD, PPARG, PTGS2, TERT, XDH |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 5.171E-05 | 3.381E-03 | AKR1B1, CYP1B1, MAPK1, MMP9, TP53 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 5.171E-05 | 3.381E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0009987; cellular process | GO:0071396; cellular response to lipid | 5.273E-05 | 3.417E-03 | AR, CDK6, CFTR, ESR1, FLT3, NPC1, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 5.409E-05 | 3.485E-03 | ESR1, PPARA, TERT |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 5.709E-05 | 3.646E-03 | AKR1B1, ALOX5, AR, CDK6, CSNK2A1, ESR1, ESR2, GSK3B, HIF1A, HPGD, LMNA, MAPK1, NR1I2, PARP1, POLB, PPARA, PPARD, PPARG, RECQL, SMN1, SMN2, TERT, TNKS, TP53, USP2 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 6.294E-05 | 3.984E-03 | CYP1A1, CYP1A2, CYP1B1 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 6.782E-05 | 4.244E-03 | ABCC1, ADRA2A, CA2, CA4, HPGD, TSHR |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 6.978E-05 | 4.316E-03 | CYP19A1, FFAR4, PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 7.268E-05 | 4.472E-03 | HIF1A, TERT, TP53 |
| MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 7.271E-05 | 4.472E-03 | AR, ESR1, GSK3B, PPARA, TP53 |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 8.181E-05 | 4.827E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 8.181E-05 | 4.827E-03 | ADRA2A, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 8.181E-05 | 4.827E-03 | TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 8.181E-05 | 4.827E-03 | CYP1A1, CYP1A2 |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 8.203E-05 | 4.827E-03 | CYP1B1, GSK3B, HPGD, MAPT, MMP9, NOX4, PPARG, PTGS2, TP53, XDH |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 8.181E-05 | 4.827E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 8.181E-05 | 4.827E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 8.181E-05 | 4.827E-03 | ALDH1A1, AR |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 8.336E-05 | 4.879E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 8.596E-05 | 5.018E-03 | AKR1B1, CDK6, CFTR, CYP1B1, MAPK1, PTGS2, TP53 |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 8.984E-05 | 5.201E-03 | CSNK2A1, ESR1, GSK3B, PPARA, PPARG, TP53, USP2 |
| BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 9.138E-05 | 5.264E-03 | ALOX15, GSK3B, HIF1A, MAPK1, MAPT, MMP9, NOX4, TNKS, TNKS2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 9.501E-05 | 5.399E-03 | CYP1A1, CYP1A2, PPARG |
| BP | GO:0065007; biological regulation | GO:0051090; regulation of DNA binding transcription factor activity | 9.614E-05 | 5.423E-03 | APP, AR, CYP1B1, ESR1, ESR2, MAPK1, PPARG, SYK |
| BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 9.974E-05 | 5.583E-03 | CD38, CYP1A2, ESR1, HPGD, PTGS2 |
| BP | GO:0009987; cellular process | GO:0001558; regulation of cell growth | 1.032E-04 | 5.733E-03 | ALOX12, CD38, CSNK2A1, ESR2, MAPT, PPARD, PPARG, TP53 |
| MF | GO:0005488; binding | GO:0043168; anion binding | 1.068E-04 | 5.919E-03 | ABCC1, ABCG2, ALOX15, APP, CDK6, CFTR, CSNK2A1, FABP3, FFAR4, FLT3, GSK3B, HPGD, HSD17B1, MAPK1, NMUR2, NOX4, PKM, PPARD, PPARG, RECQL, SYK, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 1.077E-04 | 5.921E-03 | HIF1A, PPARD, TP53 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 1.139E-04 | 6.247E-03 | AKR1B1, HIF1A, MAPK1, MAPT |
| BP | GO:0065007; biological regulation | GO:0043281; regulation of cysteine-type endopeptidase activity involved in apoptotic process | 1.190E-04 | 6.494E-03 | CSNK2A1, MAPT, MMP9, PPARG, PTGS2, XDH |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 1.214E-04 | 6.543E-03 | CYP19A1, CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0003950; NAD+ ADP-ribosyltransferase activity | 1.214E-04 | 6.543E-03 | PARP1, TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:2001234; negative regulation of apoptotic signaling pathway | 1.357E-04 | 7.012E-03 | AR, HIF1A, LMNA, MMP9, PTGS2, TERT |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 1.360E-04 | 7.012E-03 | ALOX12, ALOX15 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 1.360E-04 | 7.012E-03 | PPARA, PPARG |
| BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 1.362E-04 | 7.012E-03 | CYP1B1, HIF1A, PTGS2 |
| BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 1.362E-04 | 7.012E-03 | PARP1, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 1.362E-04 | 7.012E-03 | APP, GSK3B, PARP1 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.360E-04 | 7.012E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 1.521E-04 | 7.723E-03 | CYP19A1, CYP3A4, ESR1 |
| MF | Unclassified; | GO:0004872; receptor activity | 1.565E-04 | 7.872E-03 | ADRA2A, ADRA2C, AR, ESR1, ESR2, FFAR1, FFAR4, FLT3, HPGD, NMUR2, NPC1, NR1I2, PPARA, PPARD, PPARG, TSHR |
| BP | GO:0050896; response to stimulus | GO:0043627; response to estrogen | 1.590E-04 | 7.979E-03 | CA2, ESR1, MAPK1, PPARG |
| BP | GO:0008283; cell proliferation | GO:0050680; negative regulation of epithelial cell proliferation | 1.649E-04 | 8.237E-03 | AR, CDK6, PPARD, PPARG, XDH |
| BP | GO:0050896; response to stimulus | GO:0032868; response to insulin | 1.706E-04 | 8.481E-03 | FABP3, PARP1, PKM, PPARA, PPARG |
| BP | GO:0050896; response to stimulus | GO:0009314; response to radiation | 1.713E-04 | 8.494E-03 | APP, HIF1A, NOX4, PARP1, POLB, PTGS2, TP53, USP2 |
| CC | GO:0016020; membrane | GO:0005886; plasma membrane | 1.807E-04 | 8.943E-03 | ABCC1, ABCG2, ACHE, ADRA2A, ADRA2C, ALOX12, ALOX15, APP, AR, CA12, CA2, CA4, CD38, CFTR, CSNK2A1, ESR1, FFAR1, FFAR4, FLT3, GAA, GLO1, GSK3B, HSD17B10, MAPK1, MAPT, MMP2, NMUR2, SYK, TDP1, TERT, TSHR |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.859E-04 | 9.122E-03 | CSNK2A1, FLT3, PKM, PPARG |
| BP | GO:0008152; metabolic process | GO:0042572; retinol metabolic process | 1.876E-04 | 9.136E-03 | ALDH1A1, CYP1B1, TTR |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 1.923E-04 | 9.349E-03 | ALOX15, ESR1, GSK3B, MAPT, PARP1, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.955E-04 | 9.461E-03 | ALOX15, PPARA, PPARD, TP53 |
| BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 1.955E-04 | 9.461E-03 | GSK3B, MAPT, PARP1, TP53 |
| BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 2.012E-04 | 9.635E-03 | ADRA2A, CD38, PARP1, TNKS, TNKS2 |
| BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 2.035E-04 | 9.635E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0010871; negative regulation of receptor biosynthetic process | 2.035E-04 | 9.635E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0070212; protein poly-ADP-ribosylation | 2.035E-04 | 9.635E-03 | PARP1, TNKS |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 2.035E-04 | 9.635E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.035E-04 | 9.635E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0050543; icosatetraenoic acid binding | 2.035E-04 | 9.635E-03 | FABP3, PPARG |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 2.055E-04 | 9.687E-03 | CSNK2A1, GSK3B, MAPK1, TNKS |
| BP | GO:0032501; multicellular organismal process | GO:0090257; regulation of muscle system process | 2.066E-04 | 9.698E-03 | ADRA2A, ADRA2C, LMNA, NMUR2, PARP1, PTGS2 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 2.071E-04 | 9.698E-03 | CYP1A2, MAPK1, MMP9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.666E-08 | 1.415E-06 | AR; GSK3B; CDK6; FLT3; MMP2; MAPK1; PPARG; PTGS2; HIF1A; TP53; MMP9; PPARD |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 6.673E-09 | 1.148E-06 | APP; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; PTGS2; PTGS1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.468E-08 | 1.415E-06 | HSD17B1; ALOX5; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.694E-07 | 9.269E-06 | MAOA; GAA; ALOX15; AKR1B1; ALOX12; PTGS2; CYP3A4; CYP19A1; HSD17B10; PTGS1; PKM; HSD17B1; ALOX5; CYP1A2; ALDH1A1; CYP1A1; CD38; XDH |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 6.145E-08 | 2.642E-06 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.897E-06 | 7.118E-05 | ALOX5; ALOX15; ALOX12; PTGS2; PTGS1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 4.264E-06 | 9.167E-05 | PKM; FLT3; MAPK1; TP53; HIF1A |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.279E-05 | 2.200E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.888E-05 | 4.140E-04 | MMP2; MAPK1; ESR1; MMP9; ESR2 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.155E-05 | 2.200E-04 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; PTGS2 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.414E-05 | 2.210E-04 | MMP2; MAPK1; MMP9; TP53 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 9.090E-05 | 9.706E-04 | MMP2; MAPK1; TP53; HIF1A; ESR1; MMP9 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 6.701E-05 | 8.866E-04 | GSK3B; MAPK1; TP53; ESR1; HIF1A |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.546E-07 | 1.017E-05 | CA12; CA2; CA4; CA7 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 9.593E-05 | 9.706E-04 | POLB; CDK6; PKM; SYK; MAPK1; TP53 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 9.577E-05 | 9.706E-04 | ABCC1; CDK6; CYP1B1; MAPK1; PTGS2; TP53; MMP9 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 8.854E-05 | 9.706E-04 | CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.320E-04 | 1.081E-03 | GSK3B; MAPK1; ESR1; ESR2 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.118E-04 | 1.069E-03 | FABP3; PPARG; PPARA; PPARD |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.250E-04 | 1.081E-03 | CA2; CYP3A4; CFTR; ABCG2 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 2.992E-04 | 2.059E-03 | GSK3B; AR; MAPK1; TP53 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.393E-04 | 1.089E-03 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 3.500E-04 | 2.255E-03 | APP; GSK3B; MAPK1; MAPT; HSD17B10 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 8.086E-04 | 4.636E-03 | GSK3B; SYK; CSNK2A1; CD38; TP53 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 4.800E-04 | 2.948E-03 | HPGD; FLT3; PPARG; TP53; MMP9 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 3.539E-04 | 2.255E-03 | SYK; CSNK2A1; PARP1; PTGS2 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.637E-03 | 7.300E-03 | PARP1; LMNA; MAPK1; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.355E-03 | 6.661E-03 | GSK3B; MAPK1; PPARA; TP53 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.472E-03 | 6.841E-03 | GSK3B; CDK6; CSNK2A1; TP53 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.724E-03 | 7.300E-03 | GSK3B; CSNK2A1; TP53; PPARD |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.908E-03 | 7.815E-03 | CDK6; MAPK1; TP53; MMP9 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 8.711E-04 | 4.833E-03 | GSK3B; MAPK1; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.081E-03 | 5.637E-03 | CDK6; MAPK1; TP53 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.081E-03 | 5.637E-03 | PTGS2; TSHR; PTGS1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.139E-03 | 5.760E-03 | FLT3; MAPK1; PPARD |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.528E-04 | 1.095E-03 | MAPK1; PPARG; TP53 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.665E-03 | 7.300E-03 | CDK6; MAPK1; TP53 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.453E-03 | 6.841E-03 | GSK3B; MAPK1; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.740E-03 | 7.300E-03 | CDK6; MAPK1; TP53 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 7.707E-03 | 2.410E-02 | GSK3B; CDK6; SYK; MAPK1; TP53 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 5.776E-03 | 1.910E-02 | MAPK1; PPARA; CFTR; TSHR |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.146E-03 | 8.387E-03 | CDK6; MAPK1; TP53 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.323E-03 | 8.685E-03 | CDK6; MAPK1; TP53 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 2.323E-03 | 8.685E-03 | GSK3B; SYK; MAPK1 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 5.329E-04 | 3.161E-03 | ABCC1; CFTR; ABCG2 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 7.332E-03 | 2.335E-02 | MAPK1; PTGS2; MMP9 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 3.697E-03 | 1.325E-02 | CDK6; PTGS2; TP53 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.977E-03 | 7.908E-03 | MAOA; CYP1A2; CYP3A4 |
| hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 3.944E-03 | 1.384E-02 | THPO; FLT3; CD38 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 5.031E-03 | 1.731E-02 | CA2; CD38; CFTR |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.528E-04 | 1.095E-03 | CYP1A2; ALOX15; CYP3A4 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 9.728E-03 | 2.836E-02 | SYK; MAPK1; PTGS1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 9.301E-03 | 2.758E-02 | GSK3B; MAPK1; TP53 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 9.301E-03 | 2.758E-02 | ABCC1; MAPK1; TP53 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.403E-02 | 3.772E-02 | POLB; GSK3B; TERT; TP53 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.776E-02 | 4.627E-02 | NMUR2; ADRA2C; ADRA2A; TSHR |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.203E-02 | 3.339E-02 | SYK; MAPK1; PPARG |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.017E-02 | 2.914E-02 | GSK3B; CDK6; TP53 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.939E-02 | 4.978E-02 | CD38; MAPK1; PTGS2 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.678E-02 | 4.441E-02 | GSK3B; TP53 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.296E-02 | 3.537E-02 | PKM; MAPK1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.194E-02 | 3.339E-02 | CYP3A4; XDH |
| hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 9.126E-03 | 2.758E-02 | PKM; GLO1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 5.209E-03 | 1.757E-02 | GAA; AKR1B1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 6.278E-03 | 2.038E-02 | POLB; PARP1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 3.079E-03 | 1.127E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.269E-04 | 1.081E-03 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; ADRA2C; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1; MAOA; PTGS2; PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1; AKR1B1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; TERT; MMP2; PTGS2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; SYK; SYK; ADRA2C; MMP12; PTGS2 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; ADRA2C; PPARG |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; SYK; PTGS1; MMP12; PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2; PPARG |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| NA: NA | Edema | NA | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; MMP12; MMP12 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; PARP1; MMP2 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53; CD38 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; PTGS1; ESR1; ADRA2C; ADRA2A; PTGS2; PTGS2; PTGS2; PTGS2; ACHE; PKM |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; ACHE |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GSK3B; FFAR1; AKR1B1; PPARG |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; PTGS1; MMP2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; ESR1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; GSK3B; SYK; HIF1A; TP53; FLT3; FLT3; MAPK1; MMP9; ESR1; ESR1; PARP1; MMP2; PTGS2; ACHE; CD38; APP; CSNK2A1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; SYK |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; PTGS1 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ADRA2C; ACHE |
| NA: NA | GIST | NA | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; PTGS2; PPARG; ABCC1; ABCC1 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; PTGS1; ESR1; MMP2 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ESR1; TERT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; ESR1; ESR1; TERT |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; TERT |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1; TERT |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PPARD; PTGS2; PPARG; PPARG |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | SYK; HIF1A; TP53; FLT3; MAPK1; MMP9; MMP2; PKM |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; PPARD; MMP12; NR1I2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; PTGS2; PTGS2; ABCC1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; ESR1; PTGS2; PTGS2; PTGS2; PTGS2 |
| C00-D49: Neoplasms | Melanoma | C43 | TERT; PARP1 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT; CD38 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2; PPARG |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; ADRA2C; MAOA; PTGS2; PPARG; PPARG; ACHE; ACHE; ACHE; MAPT; APP |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; SYK; AKR1B1; PTGS2; PTGS2; PTGS2; PTGS2 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C; MAOA |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; MAOA; ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3; TERT |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| NA: NA | Menopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1; TP53; FLT3; MMP9 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| NA: NA | Male hypogonadism | NA | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| C00-D49: Neoplasms | AML | NA | FLT3 |